Business
Launch of first two products on new platform
Launch of first two products on new platform.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6379I Cambridge Cognition Holdings PLC 03 June 2014 \n\n3 June 2014\nCambridge Cognition Holdings Plc \n('Cambridge Cognition' or the 'Company')\n \nLaunch of the first two products on the new Cantab Connect platform\n \nCambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the launch of the first two iPad-based products on its new Cantab Connect digital platform, for use in clinical trials. Both of these products address the market need to assess the safety of new drugs in development, an addressable market which the Company estimates to be in excess of £60m. \n \nThe Clinical Trials Information System Adverse Effects (CTIS-AE) product enables fast, sensitive and reproducible measurement of cognitive impairment in Phase I trials. This enables early informed decisions to be made about the cognitive safety of new drugs, reducing the risk of costly late-stage failure in clinical development. Furthermore, CTIS-AE complies with FDA reviewer guidance which states that data submissions that include special studies intended to identify adverse events, such as decreased cognitive function, will be given more credence than those which do not. CTIS-AE should therefore provide a valuable tool to the numerous companies developing drugs belonging to classes that have a known cognitive safety risk. \n \nThe CTIS-Abuse Liability (CTIS-AL) product is a computerised patient-report system enabling rapid, accurate and paperless measurement of the abuse potential for investigational drugs in clinical trials. It enables companies to comply with FDA guidance which states that drug products with the potential for abuse should be assessed for liability. Current practice in abuse liability trials relies largely on pen and paper questionnaires which have inherent inaccuracies. CTIS-AL provides a digital solution, with automated administration and data collection, reducing trial workloads and costs and improving data quality. This product will meet the increasing demand for abuse liability studies to assess the addictive qualities of drugs. \n \nBoth products (CTIS-AE and CTIS-AL) are designed for GCP-compliant studies. The products comply with the European Clinical Trials Directive 2...